Drugs / VXA-G2.4-NS
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06944717 | Mar 2025 → May 2026 overdue | norovirus infectious disease | Vaxart | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07254728 | Oct 2023 → Dec 2024 | norovirus infectious disease | Vaxart | Completed | No outcome recorded |
| Phase 1 | NCT03897309 | Mar 2019 → Jan 2021 | norovirus infectious disease | Vaxart | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXA-G2.4-NS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06944717 ↗ |
| Modality | Vaccine | “Adenoviral-vector Based Oral Norovirus Vaccines Expressing GI.1 or GII.4 VP1” NCT03897309 ↗ |
| Route | Oral | “Adenoviral-vector Based Oral Norovirus Vaccines” NCT03897309 ↗ |